Crosslinking-based targeted therapy for triple-negative breast cancer
基于交联的三阴性乳腺癌靶向治疗
基本信息
- 批准号:10650998
- 负责人:
- 金额:$ 20.29万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2023
- 资助国家:美国
- 起止时间:2023-04-13 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:3-DimensionalAntibodiesAntineoplastic AgentsApoptosisBindingBiological AssayBreast Cancer CellBreast Cancer PatientBreast Cancer TreatmentBreast Cancer cell lineBreast cancer metastasisCancer Cell GrowthCause of DeathCell AggregationCellsCirculationCoupledDNADiseaseDistant MetastasisDoxorubicinDrug Delivery SystemsDrug KineticsDrug or chemical Tissue DistributionERBB3 geneEffectivenessEpidermal Growth Factor ReceptorEstrogen ReceptorsFoundationsGoalsGrowthHormone ReceptorHumanIn VitroInbred BALB C MiceIndividualInduction of ApoptosisInnovative TherapyInvadedMammary NeoplasmsMediatingMembraneMetabolicMetastatic Neoplasm to the LungMetastatic malignant neoplasm to brainMusNanostructuresNeoplasm MetastasisNew AgentsPharmaceutical PreparationsPilot ProjectsPrevention therapyPrimary NeoplasmProgesteroneProgesterone ReceptorsPrognosisProtein OverexpressionReagentRecurrent tumorResistanceSafetySeriesSiteSubgroupTestingTherapeuticWestern BlottingXenograft Modelantibody conjugatecancer cellcell motilitychemotherapycrosslinkdesigneffective therapyin vivoinhibitorinnovationmalignant breast neoplasmmigrationmortalitymouse modelnanoparticlenanoparticle drugnovelnovel therapeuticsoverexpressionpreventreceptorscaffoldsmall moleculetargeted agenttargeted treatmenttriple-negative invasive breast carcinomatumor growth
项目摘要
Abstract
The HER1 and/or HER3 receptors are overexpressed in most triple-negative breast cancers (TNBCs), a
subtype of breast cancer that lacks estrogen receptor, progesterone, and HER2 expression and is associated
with poor prognosis and a high lung and brain metastasis rate. Chemotherapy is the mainstay of TNBC treatment.
Our long-term goal is to develop more effective therapy for this aggressive subtype of breast cancer. In this
proposal, we aim to develop a novel crosslinking-based targeted therapy. For this purpose, we will create a
series of multi-functional DNA-affibody-drug nanoparticles containing multiple copies of HER1 and/or HER3
specific affibody molecules covalently coupled to a DNA nanostructure, of which the latter binds to tens of small
molecule drugs such as THZ1. In the presence of these nanoparticles, HER1+ and/or HER3+ TNBC cells will be
tightly bound together, thus preventing metastasis in its initial stage. In the cross-linked TNBC cell clusters, the
small molecule anticancer agent THZ1 reversibly bound to the nanoparticles will be released slowly, resulting in
killing of crosslinked TNBC cells. These nanoparticles can bind to HER1+ and/or HER3+ TNBC cells in primary
tumors, metastatic sites, and circulation. In our preliminary study, cultured HER1+ TNBC cells were crosslinked
together to form cell clusters with a 96% crosslinking efficiency, 99% migration inhibition, and 90% invasion
inhibition by a DNA-4ZHER1-THZ1 nanoparticle (drug-to-cargo ratio is 50).
To enhance the efficiency and overcome the resistance to HER1 inhibitors, a novel DNA-2ZHER1-2ZHER3-THZ1
nanoparticle that targets dual HER1 and HER3 will be synthesized and tested in this study. Our design and
hypothesis will be tested with the following specific aims: In specific aim 1, we will prepare a DNA-2ZHER1-2ZHER3-
drug nanoparticle for targeting HER1- and/or HER3-overexpressing TNBC. In specific aim 2, we will evaluate
the inhibition of HER1- and HER3-overexpressing TNBC cell growth and metastasis by the DNA-2ZHER1-2ZHER3-
drug nanoparticle in vitro. In specific aim 3, we will study distribution and pharmacokinetics of selected DNA-
2ZHER1-2ZHER3-drug nanoparticle in healthy mice, and to evaluate its suppression of mammary tumor growth and
metastasis in TNBC xenograft models.
If successful, this innovative approach will open a new avenue for developing new therapy for treatment of
TNBC. The pilot study will lay a foundation for further studies to investigate the utilities and mechanisms of the
new class of anticancer agents for targeted therapy.
摘要
HER 1和/或HER 3受体在大多数三阴性乳腺癌(TNBC)中过表达,
一种缺乏雌激素受体、孕酮和HER 2表达的乳腺癌亚型,
预后差,肺、脑转移率高。化疗是TNBC治疗的主要手段。
我们的长期目标是为这种侵袭性乳腺癌亚型开发更有效的治疗方法。在这
我们的目标是开发一种新的基于交联的靶向治疗。为此,我们将创建一个
一系列含有多个拷贝的HER 1和/或HER 3的多功能DNA-抗体-药物纳米颗粒
特异性亲和体分子与DNA纳米结构共价偶联,后者与数十个小分子结合
分子药物如THZ 1。在这些纳米颗粒的存在下,HER 1+和/或HER 3 + TNBC细胞将被诱导。
紧密结合在一起,从而在其初始阶段防止转移。在交联的TNBC细胞簇中,
与纳米颗粒可逆结合的小分子抗癌剂THZ 1将缓慢释放,导致
杀死交联的TNBC细胞。这些纳米颗粒可以在原代培养中结合至HER 1+和/或HER 3 + TNBC细胞。
肿瘤、转移部位和循环。在我们的初步研究中,将培养的HER 1 + TNBC细胞交联,
一起形成具有96%交联效率、99%迁移抑制和90%侵袭的细胞簇
通过DNA-4 ZHER 1-THZ 1纳米颗粒的抑制(药物与货物比为50)。
为了提高效率并克服对HER 1抑制剂的抗性,设计了一种新的DNA-2 ZHER 1 - 2 ZHER 3-THZ 1,
靶向双重HER 1和HER 3的纳米颗粒将在本研究中合成和测试。我们的设计和
假设将用以下具体目标进行检验:在具体目标1中,我们将制备DNA-2 ZHER 1 - 2 ZHER 3 - 2 ZHER-2 Z
用于靶向过表达HER 1和/或HER 3的TNBC的药物纳米颗粒。在具体目标2中,我们将评估
通过DNA-2 ZHER 1 - 2 ZHER 3-抑制HER 1-和HER 3-过表达的TNBC细胞生长和转移,
药物纳米颗粒体外研究。在具体目标3中,我们将研究所选DNA的分布和药代动力学,
2 ZHER 1 - 2 ZHER 3-药物纳米颗粒,并评估其对乳腺肿瘤生长的抑制和对肿瘤细胞增殖的抑制。
在TNBC异种移植物模型中的转移。
如果成功,这种创新方法将为开发新的治疗方法开辟一条新途径
TNBC。本试验研究将为进一步研究其效用和机制奠定基础。
用于靶向治疗的新型抗癌剂。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shengxi Chen其他文献
Shengxi Chen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
相似海外基金
University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
- 批准号:
10073243 - 财政年份:2024
- 资助金额:
$ 20.29万 - 项目类别:
Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
- 批准号:
10752129 - 财政年份:2024
- 资助金额:
$ 20.29万 - 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
- 批准号:
2339201 - 财政年份:2024
- 资助金额:
$ 20.29万 - 项目类别:
Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
- 批准号:
MR/Y008693/1 - 财政年份:2024
- 资助金额:
$ 20.29万 - 项目类别:
Research Grant
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
- 批准号:
23K14783 - 财政年份:2023
- 资助金额:
$ 20.29万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
- 批准号:
23KJ0394 - 财政年份:2023
- 资助金额:
$ 20.29万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
- 批准号:
10076445 - 财政年份:2023
- 资助金额:
$ 20.29万 - 项目类别:
Grant for R&D
PLA2G2D Antibodies for Cancer Immunotherapy
用于癌症免疫治疗的 PLA2G2D 抗体
- 批准号:
10699504 - 财政年份:2023
- 资助金额:
$ 20.29万 - 项目类别:
Genetic adjuvants to elicit neutralizing antibodies against HIV
基因佐剂可引发抗艾滋病毒中和抗体
- 批准号:
10491642 - 财政年份:2023
- 资助金额:
$ 20.29万 - 项目类别:
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
新型免疫原可引发针对血凝素头三聚体界面的广泛交叉反应抗体
- 批准号:
10782567 - 财政年份:2023
- 资助金额:
$ 20.29万 - 项目类别: